ATROVENT HFA Rx
Generic Name and Formulations:
Ipratropium bromide 17micrograms/inh; metered dose inhaler; CFC-free.
Boehringer Ingelheim Pharmaceuticals
Indications for ATROVENT HFA:
Bronchospasm associated with chronic bronchitis and emphysema.
2 inh 4 times daily; max 12 inh/day.
Allergy to atropine or its derivatives.
Not for primary treatment of acute attack. Avoid eyes. Narrow-angle glaucoma. GU obstruction. Pregnancy (Cat.B). Nursing mothers.
Caution with other anticholinergics.
Bronchitis, COPD exacerbation, dyspnea, headache, anticholinergic effects; paradoxical bronchospasm, hypersensitivity reactions.
Formerly known under the brand name Atrovent.
HFA (NO); soln (YES)
Inhaler—12.9g (200 inh); inhalation soln—contact supplier
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- No Evidence of Personality Changes Prior to Developing Cognitive Impairment, Dementia
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder